Bio Techne Corp Stock Revenue
| TECH Stock | USD 75.38 0.51 0.68% |
Bio Techne Corp fundamentals help investors to digest information that contributes to Bio Techne's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Techne's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Techne stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 1.2 B | 1.2 B |
Bio | Revenue |
Bio Techne Corp Company Revenue Analysis
Bio Techne's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Bio Techne Revenue | 1.16 B |
Most of Bio Techne's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Techne Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Bio
Projected quarterly revenue analysis of Bio Techne Corp provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Bio Techne match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Bio Techne's stock price.
Bio Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Bio Techne is extremely important. It helps to project a fair market value of Bio Stock properly, considering its historical fundamentals such as Revenue. Since Bio Techne's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bio Techne's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bio Techne's interrelated accounts and indicators.
| 0.92 | 0.93 | 0.31 | 0.91 | -0.58 | ||
| 0.92 | 1.0 | 0.37 | 1.0 | -0.27 | ||
| 0.93 | 1.0 | 0.38 | 1.0 | -0.33 | ||
| 0.31 | 0.37 | 0.38 | 0.37 | -0.01 | ||
| 0.91 | 1.0 | 1.0 | 0.37 | -0.27 | ||
| -0.58 | -0.27 | -0.33 | -0.01 | -0.27 |
Click cells to compare fundamentals
Bio Revenue Historical Pattern
Today, most investors in Bio Techne Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Techne's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bio Techne revenue as a starting point in their analysis.
Bio Techne Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Bio Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Bio Techne Corp reported 1.16 B of revenue. This is 84.8% lower than that of the Life Sciences Tools & Services sector and 56.02% higher than that of the Health Care industry. The revenue for all United States stocks is 87.72% higher than that of the company.
Bio Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Techne's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Techne could also be used in its relative valuation, which is a method of valuing Bio Techne by comparing valuation metrics of similar companies.Bio Techne is currently under evaluation in revenue category among its peers.
Bio Techne ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bio Techne's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bio Techne's managers, analysts, and investors.Environmental | Governance | Social |
Bio Techne Institutional Holders
Institutional Holdings refers to the ownership stake in Bio Techne that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bio Techne's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bio Techne's value.| Shares | Mackenzie Investments | 2024-09-30 | 2.9 M | Bank Of New York Mellon Corp | 2024-06-30 | 2.7 M | Mairs & Power Inc | 2024-09-30 | 2.7 M | Champlain Investment Partners, Llc | 2024-09-30 | 2.6 M | Massachusetts Financial Services Company | 2024-09-30 | 2.6 M | Macquarie Group Ltd | 2024-06-30 | 2.5 M | Brown Capital Management, Llc | 2024-09-30 | 2.1 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 2 M | Norges Bank | 2024-06-30 | 1.9 M | Vanguard Group Inc | 2024-09-30 | 18.3 M | Blackrock Inc | 2024-06-30 | 15 M |
Bio Fundamentals
| Return On Equity | 0.0729 | ||||
| Return On Asset | 0.0555 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 12.19 B | ||||
| Shares Outstanding | 158.89 M | ||||
| Shares Owned By Insiders | 1.03 % | ||||
| Shares Owned By Institutions | 99.41 % | ||||
| Number Of Shares Shorted | 3.53 M | ||||
| Price To Earning | 74.38 X | ||||
| Price To Book | 5.60 X | ||||
| Price To Sales | 10.22 X | ||||
| Revenue | 1.16 B | ||||
| Gross Profit | 770.22 M | ||||
| EBITDA | 310.37 M | ||||
| Net Income | 168.07 M | ||||
| Cash And Equivalents | 247.03 M | ||||
| Cash Per Share | 6.30 X | ||||
| Total Debt | 419.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 3.44 X | ||||
| Book Value Per Share | 13.46 X | ||||
| Cash Flow From Operations | 298.98 M | ||||
| Short Ratio | 3.43 X | ||||
| Earnings Per Share | 0.95 X | ||||
| Price To Earnings To Growth | 2.77 X | ||||
| Target Price | 85.25 | ||||
| Number Of Employees | 3.1 K | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 11.98 B | ||||
| Total Asset | 2.7 B | ||||
| Retained Earnings | 1.33 B | ||||
| Working Capital | 458.04 M | ||||
| Current Asset | 253.89 M | ||||
| Current Liabilities | 54.15 M | ||||
| Annual Yield | 0 % | ||||
| Five Year Return | 0.56 % | ||||
| Net Asset | 2.7 B | ||||
| Last Dividend Paid | 0.32 |
About Bio Techne Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Techne Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Techne using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Techne Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out Bio Techne Piotroski F Score and Bio Techne Altman Z Score analysis. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.32) | Dividend Share 0.32 | Earnings Share 0.95 | Revenue Per Share 7.424 | Quarterly Revenue Growth 0.045 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.